Skip to main content
Article
Utilisation of co-testing (human papillomavirus DNAtesting and cervical cytology) after treatment of CIN: a survey of GPs' awareness and knowledge
Australian Family Physician (2015)
  • Aime Munro, WA Cervical Cancer Prevention Program
  • Professor Jim Codde, The University of Notre Dame Australia
  • James Semmens, Curtin University
  • Yee Leung, The University of Western Australia
  • Katrina Spilsbury, Curtin University
  • Vincent Williams, Curtin University
Abstract
Background:
Patients have an increased risk of
persistent/recurrent cervical disease if
they received treatment for a high-grade
squamous intraepithelial lesion (HSIL).
Consequently, understanding whether
co-testing (human papillomavirus [HPV]
DNA testing and cervical cytology) is fully
utilised by general practitioners (GPs) is
paramount.
Methods:
After consultation with key stakeholders,
an anonymous, self-completion
questionnaire was developed and
disseminated to GPs who had provided
cervical cytology.
Results:
Responses were received from 745 GPs
(30.9% response rate). A significant
number (34.3%) of GPs were unaware of
the use of co-testing (HPV DNA testing
and cervical cytology) for the management
of patients after HSIL treatment.
Additionally, the majority of GPs reported
they did not ‘always’ receive a clear followup
plan for patients after treatment of an HSIL.
Discussion:
GPs require further support and education
to ensure successful adoption of co-testing
(HPV DNA testing and cervical cytology),
specifically, for patients treated for an HSIL.
Publication Date
2015
Citation Information
Munro, A., Codde, J.P., Semmens, J., Leung, L., Spilsbury, K., Williams, V., Steel, N., Cohen, P., Pavicic, H., Westoby, V., and O'Leary, P. (2015). Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs' awareness and knowledge. Australian Family Physician, 44(1-2), 64-68.